Chase Doyle


Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

December 8th 2016

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.

Ibrutinib Shows Promise in Treating GVHD After Stem Cell Transplant

December 7th 2016

An FDA-approved blood cancer drug has demonstrated encouraging findings, including an overall response rate of 67%, in treatment of patients with chronic graft-versus-host-disease that was not resolved by corticosteroids.

Study Supports Use of Anthracyclines for Early, HER2-Negative Breast Cancer

July 29th 2016

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.

TCH+P Still Standard Choice for Patients With HER2+ Breast Cancer

July 10th 2016

Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.

Ramucirumab Improves Survival in HCC Subgroup

January 17th 2015

An analysis of patients with advanced hepatocellular carcinoma and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.